IMPORTANT: UPDATED Guidance for Patients on COVID-19 including Vaccine Information»
Help us continue to support the patients served by AAMDSIF by registering to run in our 2021 Virtual Walk and 5K or simply by donating. We look forward to walking and running with you the week of April 24 - May 1, 2021, and continuing the celebration of the brave patients and families that are fighting
This is an adaptive two-stage phase II
This virtual support group is to help support patients between the ages of 18-30 who have been diagnosed with
Catherine Chittick, RN, BSN is an oncology nurse at the Massachusetts General Hospital (MGH), where she has been employed for five years since the start of her career.
Jenna Moran, MSN, FNP-BC, is an oncology nurse practitioner with the Leukemia department at the Massachusetts General Hospital Cancer Center in Boston, MA. She has experience in both the ambulatory and inpatient care settings. Her current areas of clinical focus include
Aura Ramos, RN, BSN, is a leukemia research nurse at the Massachusetts General Hospital Cancer Center in Boston for the past 6 years. Aura has over 16 years of nursing experience caring for oncology patients in the ambulatory and inpatient setting. Prior to becoming a research nurse, she worked as a staff nurse on the leukemia and
Tamibarotene (brand name: Amnolake), also called retinobenzoic acid, is orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity against acute promyelocytic leukaemia (APL) .
SY-1425 is a selective retinoic acid receptor alpha (RARα) agonist for genomically defined subsets of patients whose disease is characterized by the overexpression of the RARA gene. SY-1425 is in clinical trials for RARA-positive patients.
If you are interested in learning more about your possible participation in this clinical trial, please complete the form. Your information will be forwarded directly to the sponsoring company.
A subset of participants have MDS characterized by an overexpression of the RARA gene. A blood test will be used to identify participants with RARA-positive MDS. Assessment of the RARA biomarker for study eligibility will be done by collection of blood samples from potential study participants at the pre-screening visit and testing at a central laboratory.
